Danaher Co. (NYSE:DHR) Shares Purchased by CIBC Asset Management Inc

CIBC Asset Management Inc grew its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 3.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 204,363 shares of the conglomerate's stock after buying an additional 6,086 shares during the quarter. CIBC Asset Management Inc's holdings in Danaher were worth $56,780,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Sargent Investment Group LLC grew its stake in shares of Danaher by 12.3% in the third quarter. Sargent Investment Group LLC now owns 12,636 shares of the conglomerate's stock worth $3,513,000 after acquiring an additional 1,384 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Danaher by 4.5% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,812 shares of the conglomerate's stock valued at $5,230,000 after buying an additional 807 shares in the last quarter. KBC Group NV lifted its position in Danaher by 36.8% in the third quarter. KBC Group NV now owns 282,386 shares of the conglomerate's stock worth $78,508,000 after buying an additional 76,017 shares during the last quarter. Kovack Advisors Inc. boosted its stake in shares of Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate's stock worth $346,000 after purchasing an additional 41 shares during the period. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Danaher by 0.5% in the third quarter. Oppenheimer & Co. Inc. now owns 25,120 shares of the conglomerate's stock worth $6,984,000 after buying an additional 116 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Barclays decreased their target price on Danaher from $285.00 to $275.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Evercore ISI boosted their target price on Danaher from $275.00 to $278.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Raymond James decreased their price objective on shares of Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a report on Wednesday, October 23rd. Finally, Robert W. Baird reduced their target price on Danaher from $278.00 to $277.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $287.16.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company's stock, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Danaher Trading Down 4.2 %

DHR stock traded down $10.02 during trading on Friday, reaching $229.36. 3,350,518 shares of the stock were exchanged, compared to its average volume of 2,750,712. The business has a 50 day moving average price of $262.91 and a 200-day moving average price of $260.49. Danaher Co. has a 1 year low of $206.30 and a 1 year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $165.66 billion, a price-to-earnings ratio of 45.00, a P/E/G ratio of 4.44 and a beta of 0.85.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm's quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 earnings per share. On average, research analysts predict that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.47%. Danaher's dividend payout ratio is currently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.